LIFECORE BIOMEDICAL, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- LIFECORE BIOMEDICAL, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 0.00 shares.
- LIFECORE BIOMEDICAL, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 0.00 shares.
- LIFECORE BIOMEDICAL, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-03-31 was 0.00 shares.
- LIFECORE BIOMEDICAL, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2024-11-24 was 0.00 shares.
- LIFECORE BIOMEDICAL, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 95.80K shares, a 519.10% increase from fiscal 2023.
- LIFECORE BIOMEDICAL, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 15.47K shares, a 90.41% decline from fiscal 2022.
- LIFECORE BIOMEDICAL, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 161.41K shares.
- LIFECORE BIOMEDICAL, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2021 was 0.00 shares, a 100.00% decline from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | |
| 2026-03-31 | 0.00 shares 10-Q · filed 2026-05-06 | |
| 2025-03-31 | 0.00 shares 10-Q · filed 2026-05-06 | |
| 2024-11-24 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-01-02 | 0.00 shares derived: sum of 4 quarters · filed 2025-01-02 |
| 2024-08-25 | 0.00 shares 10-Q · filed 2024-10-04 | 0.00 shares derived: sum of 4 quarters · filed 2024-10-04 |
| 2024-05-26 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-08-26 | 95.80K shares 10-K · filed 2024-08-26 |
| 2024-02-25 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-08-09 | |
| 2023-11-26 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | |
| 2023-08-27 | 95.80K shares 10-Q · filed 2024-08-09 | |
| 2023-05-28 | 15.47K shares 10-K · filed 2024-03-20 | |
| 2022-05-29 | 161.41K shares 10-K · filed 2024-03-20 | |
| 2021-05-30 | 0.00 shares 10-K/A · filed 2023-03-16 | |
| 2020-05-31 | 163.33K shares 10-K/A · filed 2023-03-16 | |
| 2019-05-26 | 116.83K shares 10-K · filed 2021-07-29 | |
| 2018-05-27 | 29.33K shares 10-K · filed 2020-08-14 | |
| 2015-05-31 | 0.00 shares 10-K · filed 2015-07-31 | |
| 2014-05-25 | 0.00 shares 10-K · filed 2015-07-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |